false
0001725430
0001725430
2026-08-19
2026-08-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): August 19, 2026
INTELLIGENT
BIO SOLUTIONS INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-39825 |
|
82-1512711 |
(State
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
employer
identification
no.) |
135
West 41st Street, 5th Floor
New
York, NY 10036
(Address
of principal executive offices, including zip code)
Registrant’s
telephone number, including area code: (646) 790-5756
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.01 par value |
|
INBS |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02 Results of Operations and Financial Condition.
On
August 19, 2026, Intelligent Bio Solutions Inc. (the “Company”) issued a press release (the “Press Release”)
announcing financial results for the three months and full fiscal year ended June 30, 2026. A copy of the Press Release is furnished
as Exhibit 99.1 to this Current Report on Form 8-K.
The
information furnished in this Current Report on Form 8-K under Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or
otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities
Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference
in such filing.
Item
9.01 Financial Statements and Exhibits.
| No. |
|
Description |
| 99.1 |
|
Press release dated August 19, 2026 |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date: August 19, 2026 |
|
|
| |
INTELLIGENT BIO SOLUTIONS INC. |
| |
|
|
| |
By: |
/s/ Spiro Sakiris |
| |
Name: |
Spiro Sakiris |
| |
Title: |
Chief Financial Officer |
Exhibit
99.1
Intelligent
Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge
Growth
Reader
installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units
Full
year gross profit margin expanded to 48.63%, up 778 basis points year-over-year
502
active customers as of June 30, 2026, reflecting continued commercial momentum across safety-critical industries
Company
made substantial progress toward FDA clearance and planned market expansion during the year
NEW
YORK, August 19, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a
medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational
highlights for the full year ended June 30, 2026, and provided a business update.
“Fiscal
2026 was a year of clear, compounding progress across every aspect of our business,” said Harry Simeonidis, President and CEO
at Intelligent Bio Solutions. “We delivered record annual revenue of $4.2 million, a 38% increase year-over-year, driven by
a 22% expansion in our reader installed base and a 35% increase in consumable cartridges. Our razor-razorblade model is gaining scale,
with hardware placements generating the installed base and growing consumable utilization delivering recurring revenue. Entering fiscal
2027, we are focused on three priorities: sustaining the operational improvements driving gross margin expansion, continuing to accelerate
commercial growth, and advancing our FDA regulatory program toward planned U.S. market entry. To that end, we have completed all clinical
data collection across our FDA 510(k) clinical study program. Analysis of collected data is underway, and we remain on track for our
FDA submission.”
“The
financial results for fiscal 2026 reflect a business that is scaling with improving unit economics,” said Spiro Sakiris, CFO
at Intelligent Bio Solutions. “Full-year gross profit grew 64% to $2.05 million and gross margin expanded 778 basis points to
48.63%. These improvements are a result of our transition to Syrma Johari as a high-quality, lower-cost manufacturing partner, an optimized
product mix weighted toward higher-margin cartridge consumables, and the operational leverage that comes from growing volumes across
a more efficient production base. Our sustained investment in marketing, sales, product awareness, and customer support has been the
direct commercial driver behind our 38% revenue growth and the expanding utilization we are seeing across our installed base.”
Full
Year Fiscal 2026 Financial Highlights
| ● | Total
revenue of $4,215,175, up 38% year-over-year from $3,052,532. |
| ● | Revenue
increase of $1,162,643 year-over-year. |
| ● | Gross
profit of $2,049,994, up 64% year-over-year from $1,246,859. |
| ● | Gross
profit margin of 48.63%, up from 40.85% - an improvement of 778 basis points. |
| ● | Reader
installed base of 1,886 units as of June 30, 2026, up 22% from 1,545 units as of June 30,
2025. |
| ● | Total
consumable cartridges of 106,500 units, up 35% from 78,750 in fiscal 2025. |
| ● | 502
active customers as of June 30, 2026. |
Progress
Toward FDA Clearance and U.S. Market Expansion
INBS
made substantial progress throughout fiscal 2026 in advancing its FDA 510(k) submission, supporting its planned entry into the multi-billion-dollar
U.S. drug screening market beyond current Forensic Use Only settings. The Company’s regulatory program accelerated significantly,
underpinned by a series of clinical and technical studies:
| ● | Initiated
and completed a clinical cut-off study evaluating codeine detection cut-off levels in 40
adults, advancing the clinical evidence base for the 510(k) program. |
| ● | Completed
penetration testing, with no major vulnerabilities identified, strengthening the cybersecurity
component of the submission package. |
| ● | Initiated
a multi-site method comparison study, designed to evaluate system accuracy when operated
by intended end-users. The study was completed in early fiscal 2027. |
| ● | Initiated
an interference study examining the impact of everyday substances on the Intelligent Fingerprinting
Drug Screening System. The study was completed in early fiscal 2027. |
| ● | Initiated
precision testing, evaluating reproducibility across varied manufacturing conditions and
operating environments. The study was completed in early fiscal 2027, confirming reproducibility
across more than 1,600 tests, three production runs, and three independent testing sites. |
| ● | Initiated
a usability study designed to evaluate how effectively operators could be trained to use
the Intelligent Fingerprinting Drug Screening System. The study was completed in early fiscal
2027. |
| ● | Initiated
validation study for a rapid drug screening cartridge targeting 70% faster results. |
| ● | Strengthened
the Company’s European intellectual property portfolio with its eighth patent grant,
further protecting its proprietary fingerprint drug screening technology. |
| ● | The
Company’s FDA 510(k) submission is on track for the second half of calendar 2026, progressing
toward planned entry into the U.S. market, the world’s largest drug screening market. |
Commercial
Growth and Market Expansion
INBS
continued to expand its commercial presence across international markets throughout fiscal 2026, supported by targeted investment in
marketing, sales, and customer support infrastructure.
| ● | Active
customer base grew to 502 accounts as of June 30, 2026. |
| ● | Reader
installed base expanded 22% to 1,886 units, with each new placement creating the recurring
consumable demand that underpins the Company’s revenue model. |
| ● | Total
consumable cartridges grew 35% to 106,500 units, outpacing the rate of installed base growth
and confirming deepening utilization among existing customers. |
| ● | Commercial
traction extended across safety-critical sectors including construction, manufacturing, transport
and logistics, and mining, with continued growth across the UK, Europe, APAC, and the Middle
East. |
| ● | Strategic
partnership secured with Bouygues UK, part of global construction group Bouygues Construction,
for a drug-testing rollout, adding a significant new customer in a high-profile, safety-critical
environment. |
| ● | Strategic
manufacturing transition to Syrma Johari, a high-quality, lower-cost manufacturing partner,
with initial production runs successfully completed and shipments underway. This partnership
is delivering a significant reduction in manufacturing costs, directly contributing to gross
margin expansion. |
Operational
Efficiencies Strengthening Business Fundamentals
The
improvement in gross profit margin from 40.85% to 48.63% year-over-year reflects the structural progress INBS has made in its production
and commercial operations throughout fiscal 2026:
| ● | The
transition of reader manufacturing is expected to be transformational for the Company’s
cost structure and is expected to support long-term margin improvement. This positions INBS
to achieve materially stronger unit economics as the installed base and production volumes
continue to grow. |
| ● | Increasing
economies of scale in manufacturing and distribution as production volumes grew. |
| ● | Continued
optimization of product mix, with higher-margin cartridge consumables representing a growing
proportion of total revenue. |
| ● | Increased
investment in customer support, contributing directly to higher consumables utilization rates
across the installed base and reinforcing recurring revenue generation. |
About
Intelligent Bio Solutions Inc.
Intelligent
Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The
Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat
analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the
test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis.
With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical
industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport
and logistics firms, mining, drug treatment organizations, and coroners.
For
more information, visit: https://ibs.inc/
Forward-Looking
Statements
Some
of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties.
Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s
ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and
collaborations, secure regulatory clearance or approvals, and timelines to enter the U.S. market, among others. Although Intelligent
Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual
results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify
forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,”
“plans,” “projects,” “intends,” “potential,” “may,” “could,”
“might,” “will,” “should,” and “approximately,” or other words that convey uncertainty
of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and
unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the
U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release.
Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events
or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company
Contact
Intelligent
Bio Solutions Inc.
info@ibs.inc
Investor
& Media Contact
Valter
Pinto, Managing Director
KCSA
Strategic Communications
PH:
(212) 896-1254
INBS@kcsa.com
—
Financial tables to follow —
Intelligent
Bio Solutions Inc.
Consolidated
Balance Sheets
| | |
As
of June 30, | | |
As
of June 30, | |
| | |
2026 | | |
2025 | |
| ASSETS | |
| | | |
| | |
| Current assets | |
| | | |
| | |
| Cash
and cash equivalents | |
$ | 3,992,312 | | |
$ | 1,019,909 | |
| Accounts
receivable, net | |
| 848,464 | | |
| 594,614 | |
| Inventories,
net | |
| 418,577 | | |
| 635,215 | |
| Research
and development tax incentive receivable | |
| 806,951 | | |
| 734,408 | |
| Assets
held for sale | |
| - | | |
| 327,500 | |
| Prepaid
expenses and other current assets | |
| 1,030,932 | | |
| 826,976 | |
| Total
current assets | |
| 7,097,236 | | |
| 4,138,622 | |
| Property and equipment, net | |
| 294,399 | | |
| 251,325 | |
| Operating lease right-of-use
assets | |
| 1,751,040 | | |
| 69,520 | |
| Intangibles,
net | |
| 2,799,161 | | |
| 3,790,319 | |
| Total
assets | |
$ | 11,941,836 | | |
$ | 8,249,786 | |
| | |
| | | |
| | |
| LIABILITIES
AND SHAREHOLDERS’ EQUITY | |
| | | |
| | |
| Current liabilities | |
| | | |
| | |
| Accounts
payable and accrued expenses | |
$ | 4,130,213 | | |
$ | 4,534,246 | |
| Current
portion of operating lease liabilities | |
| 147,005 | | |
| 84,659 | |
| Current
employee benefit liabilities | |
| 651,706 | | |
| 534,990 | |
| Notes
payable | |
| - | | |
| 197,146 | |
| Total
current liabilities | |
| 4,928,924 | | |
| 5,351,041 | |
| Employee benefit liabilities,
less current portion | |
| 49,931 | | |
| 84,921 | |
| Operating
lease liabilities, less current portion | |
| 1,672,155 | | |
| - | |
| Total
liabilities | |
| 6,651,010 | | |
| 5,435,962 | |
| Commitments and contingencies | |
| | | |
| | |
| | |
| | | |
| | |
| Shareholders’
equity | |
| | | |
| | |
| Common
stock, $0.01 par value, 100,000,000 shares authorized, 2,905,615 and 2,905,603 shares issued and outstanding, as of June 30, 2026,
respectively; 732,339 and 732,327 shares issued and outstanding, as of June 30, 2025, respectively* | |
| 29,056 | | |
| 7,324 | |
| Treasury
stock, at cost, 12 shares as of June 30, 2026 and 2025, respectively* | |
| (1 | ) | |
| (1 | ) |
| Additional
paid-in capital* | |
| 80,992,006 | | |
| 65,849,822 | |
| Accumulated
deficit | |
| (74,964,040 | ) | |
| (62,533,065 | ) |
| Accumulated
other comprehensive loss | |
| (546,186 | ) | |
| (327,944 | ) |
| Total
consolidated Intelligent Bio Solutions Inc. equity | |
| 5,510,835 | | |
| 2,996,136 | |
| Non-controlling
interest | |
| (220,009 | ) | |
| (182,312 | ) |
| Total
shareholders’ equity | |
| 5,290,826 | | |
| 2,813,824 | |
| TOTAL
LIABILITIES AND SHAREHOLDERS’ EQUITY | |
$ | 11,941,836 | | |
$ | 8,249,786 | |
| * |
Common
stock and per share amounts have been retroactively adjusted to reflect a 1-for-10 reverse stock split effected on December 15, 2025,
throughout the consolidated financial statements unless otherwise stated. |
Intelligent
Bio Solutions Inc.
Consolidated
Statements of Operations and Other Comprehensive Income (Loss)
| | |
Year
ended June 30, | |
| | |
2026 | | |
2025 | |
| Revenue | |
$ | 4,215,175 | | |
$ | 3,052,532 | |
| Cost
of revenue (exclusive of amortization shown separately below) | |
| (2,165,181 | ) | |
| (1,805,673 | ) |
| Gross profit | |
| 2,049,994 | | |
| 1,246,859 | |
| | |
| | | |
| | |
| Other income | |
| | | |
| | |
| Government
support income | |
| 677,776 | | |
| 816,901 | |
| | |
| | | |
| | |
| Operating expenses | |
| | | |
| | |
| Selling,
general and administrative expenses | |
| (10,502,161 | ) | |
| (8,918,468 | ) |
| Development
and regulatory approval expenses | |
| (3,371,292 | ) | |
| (2,396,513 | ) |
| Depreciation
and amortization | |
| (1,163,847 | ) | |
| (1,207,875 | ) |
| Impairment
of long-lived assets | |
| (298,555 | ) | |
| (220,062 | ) |
| Total
operating expenses | |
| (15,335,855 | ) | |
| (12,742,918 | ) |
| Loss from operations | |
| (12,608,085 | ) | |
| (10,679,158 | ) |
| | |
| | | |
| | |
| Other income (expense), net | |
| | | |
| | |
| Interest
expense | |
| (10,736 | ) | |
| (26,339 | ) |
| Realized
foreign exchange gain (loss) | |
| 39,820 | | |
| (911 | ) |
| Interest
income | |
| 110,329 | | |
| 101,522 | |
| Total
other income, net | |
| 139,413 | | |
| 74,272 | |
| Net loss | |
| (12,468,672 | ) | |
| (10,604,886 | ) |
| Net
loss attributable to non-controlling interest | |
| (37,697 | ) | |
| (36,153 | ) |
| Net
loss attributable to Intelligent Bio Solutions Inc. | |
$ | (12,430,975 | ) | |
$ | (10,568,733 | ) |
| | |
| | | |
| | |
| Other comprehensive (loss)
income | |
| | | |
| | |
| Foreign
currency translation (loss) gain | |
| (218,242 | ) | |
| 384,670 | |
| Total
other comprehensive (loss) income | |
| (218,242 | ) | |
| 384,670 | |
| Comprehensive loss | |
| (12,686,914 | ) | |
| (10,220,216 | ) |
| Comprehensive
loss attributable to non-controlling interest | |
| (37,697 | ) | |
| (36,153 | ) |
| Comprehensive
loss attributable to Intelligent Bio Solutions Inc. | |
$ | (12,649,217 | ) | |
$ | (10,184,063 | ) |
| | |
| | | |
| | |
| Net
loss per share, basic and diluted* | |
$ | (8.44 | ) | |
$ | (20.04 | ) |
| Weighted
average shares outstanding, basic and diluted* | |
| 1,472,744 | | |
| 527,364 | |
| * |
Common
stock and per share amounts have been retroactively adjusted to reflect a 1-for-10 reverse stock split effected on December 15, 2025,
throughout the consolidated financial statements unless otherwise stated. |
